Rare irAEs associated with immune checkpoint inhibitor therapy
Rare irAEs can occur in nearly all organ systems. Although it is difficult to attribute causation of an AE to ICIs, it is important for clinicians to be aware of possible AEs to rapidly diagnose and treat potential symptoms. Further research should focus on strategies to improve recognition of rare irAEs.
Authors
- Sean Ngo (ORCID: https://orcid.org/0000-0001-7298-2662)
- AJAY SHESHADRI
- Ashley Aaroe (ORCID: https://orcid.org/0000-0002-9494-6985)
- Bryan P. Schneider (ORCID: https://orcid.org/0000-0003-1868-7739)
- Maria Julia Moura Nascimento Santos (ORCID: https://orcid.org/0000-0001-5743-9290)
- Aabid Shariff
- Yuanteng Jeff Li (ORCID: https://orcid.org/0009-0002-2611-5562)
- Rachel Mortan (ORCID: https://orcid.org/0009-0003-0698-9745)
- Hao Chi Zhang (ORCID: https://orcid.org/0000-0003-0330-0167)
- Raakhi Menon
- Anisha B. Patel
- Andres Caleb Urias Rivera
- Anirudha Chatterjee
- Devin M. Garza
- Jarrett Rong
- Anusha Thomas
- Cristhiam Rojas Hernandez
- Hamza Salim
- Faraz Jafri
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Duke University (US)
- Baylor College of Medicine (US)
- University of Michigan (US)
- The University of Texas Health Science Center (US)
- The University of Texas Medical Branch at Galveston (US)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2026-02-10
- DOI
- https://doi.org/10.1080/14740338.2026.2629998
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00